{"result": "(\"entity\"<|>HOMOCISTEÍNA<|>EVENT<|>Homocisteína is an amino acid that accumulates in the body due to various metabolic disorders, leading to clinical manifestations and requiring diagnosis and treatment.)\n##\n(\"entity\"<|>METIONINA<|>EVENT<|>Metionina is an essential amino acid involved in various metabolic processes, including the metabolism of homocisteína.)\n##\n(\"entity\"<|>CISTEÍNA<|>EVENT<|>Cisteína is a non-essential amino acid that plays a crucial role in the metabolism of homocisteína and is often supplemented in dietary treatments.)\n##\n(\"entity\"<|>CISTATIONINA<|>EVENT<|>Cistationina is an intermediate in the metabolism of homocisteína and is synthesized from homocisteína and serina.)\n##\n(\"entity\"<|>SERINA<|>EVENT<|>Serina is an amino acid that participates in the metabolic pathway of homocisteína.)\n##\n(\"entity\"<|>CISTATIONINA β-SINTETASA<|>EVENT<|>Cistationina β-sintetasa is an enzyme that catalyzes the conversion of homocisteína to cistationina.)\n##\n(\"entity\"<|>TROMBOEMBOLISMO<|>EVENT<|>Tromboembolismo is a clinical manifestation associated with elevated levels of homocisteína.)\n##\n(\"entity\"<|>SÍNDROME DE MARFAN<|>EVENT<|>Síndrome de Marfan is a genetic disorder with clinical manifestations similar to those caused by elevated homocisteína levels.)\n##\n(\"entity\"<|>DIAGNÓSTICO<|>EVENT<|>Diagnóstico refers to the process of identifying the presence of elevated homocisteína levels through plasma concentration tests.)\n##\n(\"entity\"<|>TRATAMIENTO DIETÉTICO-NUTRICIONAL<|>EVENT<|>Tratamiento dietético-nutricional involves dietary management to control levels of homocisteína and related amino acids.)\n##\n(\"relationship\"<|>HOMOCISTEÍNA<|>METIONINA<|>Homocisteína is derived from the metabolism of Metionina, indicating a direct biochemical relationship<|>8)\n##\n(\"relationship\"<|>HOMOCISTEÍNA<|>CISTEÍNA<|>Cisteína is essential for the metabolism of homocisteína, showing a metabolic dependency<|>8)\n##\n(\"relationship\"<|>HOMOCISTEÍNA<|>CISTATIONINA<|>Cistationina is synthesized from homocisteína, indicating a direct metabolic relationship<|>8)\n##\n(\"relationship\"<|>HOMOCISTEÍNA<|>SERINA<|>Serina is involved in the metabolic pathway that produces homocisteína, indicating a biochemical relationship<|>8)\n##\n(\"relationship\"<|>HOMOCISTEÍNA<|>TROMBOEMBOLISMO<|>Elevated levels of homocisteína are associated with the risk of tromboembolismo, indicating a clinical relationship<|>7)\n##\n(\"relationship\"<|>HOMOCISTEÍNA<|>SÍNDROME DE MARFAN<|>The clinical manifestations of elevated homocisteína levels are similar to those of síndrome de Marfan, indicating a relationship based on symptoms<|>6)\n##\n(\"relationship\"<|>HOMOCISTEÍNA<|>DIAGNÓSTICO<|>Diagnóstico is the process of identifying elevated homocisteína levels, indicating a direct relationship in clinical practice<|>9)\n##\n(\"relationship\"<|>HOMOCISTEÍNA<|>TRATAMIENTO DIETÉTICO-NUTRICIONAL<|>Tratamiento dietético-nutricional aims to manage and control homocisteína levels, indicating a direct relationship in treatment<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ada (figura 3)21; también puede estar ocasionada de forma muy infrecuente por una alteración en el transporte intracelular de cobalamina, manifestándose solo con homocistinuria, con aciduria metilmalónica o ambas. El resultado de cualquiera de las posibles causas es un acúmulo de homocisteína, homocistina y metionina y una disminución de cisteína y taurina en el organismo.\n\n```mermaid\ngraph TD\n    THF --> Met\n    Met --> DimetilGly\n    Met --> S-adenosil_metil_transferasa\n    S-adenosil_metil_transferasa --> S-adenosilMet\n    S-adenosilMet --> Metil_transferasa\n    Metil_transferasa --> S-adenosilhomoCys\n    S-adenosilhomoCys --> Adenosil_homocisteinasa\n    Adenosil_homocisteinasa --> HomoCys\n    HomoCys --> Betaína\n    HomoCys --> Cistationina_β-sintetasa\n    Cistationina_β-sintetasa --> Cistationina\n    Cistationina --> Cistationinasa\n    Cistationinasa --> Homoserina\n    Homoserina --> α-cetobutirato\n    Cistationinasa --> Cys\n    Cys --> Cistina\n    Cys --> Taurina\n    Glutatión <--> Cys\n    HomoCys_metil_transferasa --> Met\n    Cobalamina --> HomoCys_metil_transferasa\n    5-metilTHF --> HomoCys_metil_transferasa\n    Serina --> HomoCys\n    Piridoxina --> Cistationina_β-sintetasa\n```\n\nFigura 3. Metabolismo de la metionina. Cys: cisteína; Gly: glicina; Met: metionina; R: radical; THF: tetrahidrofolato. En azul, enzimas; en negrita, coenzimas.\n---\n# BLOQUE: PROTEÍNAS Y AMINOÁCIDOS\n\n## 4.2. Manifestaciones clínicas\n\nLa severidad de la enfermedad está relacionada con los niveles de homocisteína y otros derivados disulfuro, así como con la precocidad del diagnóstico y comienzo del tratamiento. Las manifestaciones son en parte similares al síndrome de Marfan e incluyen: osteoporosis, aracnodactilia, pectum excavatum o carinatum, pies cavos, genu valgum, escoliosis, luxación del cristalino, trombosis intravascular y tromboembolismo e, incluso, retraso mental22, 23.\n\n## 4.3. Diagnóstico y control\n\nLos niveles plasmáticos de Met pueden ser normales (5-40 μmol/l, 0,1-0,6 mg/dl) en el neonato afecto, por lo que muchas veces solo se diagnostica tras el inicio de los síntomas o mediante una concentración de homocisteína total en plasma o suero superior a 15 μmol/l. El control evolutivo se realiza mediante los niveles plasmáticos de Met y homocisteína (deseable: total < 50 μmol/l y libre <10 μmol/l)23.\n\n## 4.4. Tratamiento dietético-nutricional\n\nEs preciso limitar el aporte de PNAVB a 1,5-1,8 g/kg/día en los niños, disminuyendo el aporte de alimentos ricos en proteínas, pudiéndose dar algo más de legumbres y gelatina al contener menos Met. Se emplea un sistema de intercambio similar al de la fenilcetonuria (como tabla 2, aunque sin restricción de aspartamo), considerando que 1 g de proteína natural equivale a 20-25 mg de Met, tolerándose una cantidad diaria muy variable entre 150 y 900 mg, pero muy constante en el mismo paciente. Puede ser necesario emplear suplementos con aa esenciales, enriquecido en cisteína (Cys) y micronutrientes y sin Met, repartido entre las comidas. Con este fin se emplean: HCU gel®, HCU express®, HCU cooler 15®, XMET Analog®, XMET Maxamaid®, XMET Maxamum®, XMET Homidon® (95% aa sin Met), HOM 1® y HOM 2®.\n\nEs imprescindible aportar la energía suficiente para evitar el catabolismo proteico y conseguir el adecuado crecimiento y desarrollo, para lo que se emplean suplementos bajos en proteínas junto con los alimentos.\n\n## 4.5. Otros tratamientos22, 23\n\na. Aporte de los productos deficitarios de la reacción afectada. Es preciso incrementar Cys, que se ha convertido en esencial, y para ello se aportan 100 mg/kg/día de L-cistina, que logra mantener la síntesis de cistationina y taurina, que son necesarias para el metabolismo cerebral.\n\nb. Estimulación de la actividad\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}